Immunotherapy: Can we include vaccines with stem-cell transplantation?

Nature Reviews Clinical Oncology

Volumn 6, Issue 9, 2009, Pages 503-505

  Barrett, John ^a   Rezvani, Katayoun ^b  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; CANCER VACCINE; CYCLOSPORIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN 70; IMATINIB; MONOCLONAL ANTIBODY PR1; MONTANIDE ISA 51; PEPTIDE VACCINE; PROTEIN TYROSINE KINASE INHIBITOR; WT1 PROTEIN;

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER RELAPSE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; GRAFT VERSUS HOST REACTION; HLA SYSTEM; HUMAN; LEUKEMIA; LOW DRUG DOSE; MYELOABLATIVE CONDITIONING; MYELOID LEUKEMIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN MANIFESTATION;

HUMANS; IMMUNOTHERAPY; LEUKEMIA; RECURRENCE; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS; VACCINES, SUBUNIT;

EID: 70450195269     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2009.115     Document Type: Article

References (10)

1. Rezvani, K. et al. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 111, 236-242 (2008).
2. Oka Y. et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc. Natl Acad. Sci. USA 101, 13885-13890 (2004).
3. Qazilbash, M. H. et al. PR1 Vaccine elicited immunological response after hematopoietic stem cell transplantation is associated with better clinical response and event-free survival. ASH Annual Meeting Abstracts 110, 577 (2007).
4. Bocchia, M. et al. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet 365, 657-662 (2005).
5. Li, Z. et al. Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein and chronic myelogenous leukemia. Clin. Cancer Res. 11, 4460-4468 (2005).
6. Rezvani, K. & Barrett, A. J. Characterizing and optimizing immune responses to leukaemia antigens after allogeneic stem cell transplantation. Best Pract. Res. Clin. Haematol. 21, 437-453 (2008).
7. Rezvani K. et al. Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem cell transplantation for acute lymphoblastic leukemia. Blood 110, 1924-1932 (2007).
8. + T cells that recognize and kill human malignant mesothelioma tumor cells. Clin. Cancer Res. 13, 4547-4555 (2007).
9. Clave, E., Molldrem, J., Hensel, N., Raptis, A. & Barrett, A. J. Donor-recipient polymorphism of the proteinase 3 gene: a potential target for T-cell alloresponses to myeloid leukemia. J. Immunother. 22, 1-6 (1999).
10. Mielke, S. et al. A clinical scale selective allodepletion approach for the treatment of HLA-mismatched and matched donor-recipient pairs using expanded T lymphocytes as antigen-presenting cells and a TH9402-based photodepletion technique. Blood 111, 4392-4402 (2007).